Reckitt Capitalizes As COVID Moves From Pandemic To Endemic
Executive Summary
Reckitt's OTC sales jumped 60% in the first half of 2022 as the milder omicron COVID-19 variant drove up demand for its leading cold and flu brands. This strong showing has led the firm to raise its full-year group sales guidance from 1-4% to 5-8%.
You may also be interested in...
US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall
House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.
Reckitt Sees Positive Signs For Cold & Flu Brands After Difficult First Half
Reckitt is seeing good signs in the US that cold and flu incidence is returning to more normal levels. However, the upswing came too late to materially impact first-half sales at its Health business, which posted turnover down 14%.
New Iron Source Granted EU Novel Food Approval
Ireland's Nemysis Limited has secured authorization from the European Commission to market in the EU a novel form of iron in supplements for both adults and children.